Hengenix, A Henlius Company

Home
United States
Milpitas, CA
Hengenix, A Henlius Company

We focus on developing and delivering high-quality, innovative, and affordable medical solutions.

06/13/2023

Is your job putting you at risk of developing small cell lung cancer (SCLC)? A new 2023 study confirms that to***co consumption is the leading factor in developing SCLC, but also points to occupations with increased risk factors for SCLC. Metal workers (35.8%), painters (21.2%) , and stonemasons (13.9%) were the most frequent known-risk occupations among the study's participants.

Read more: https://www.nature.com/articles/s41598-023-31991-0

06/01/2023

For patients living with small cell lung cancer, our treatment pairing Serplulimab with chemotherapy could be the breath of fresh air they need.

Learn more about eligibility for our patient trials today: https://www.smallcelllungcancertrial.com/find-a-clinical-trial

05/25/2023

For patients with small cell lung cancer (SCLC), new treatments are improving their outcomes, while ongoing trials are showing promise for even better survival in the future.

Dr. Ravi Salgia, professor and chair in the Department of Medical Oncology at City of Hope, strongly encourages eligible SCLC patients "to consider participation in a clinical trial, especially if they have sensitive disease, meaning that they experienced a relapse less than six months after completing their original treatment."

Learn more: https://www.curetoday.com/view/educated-patient-lung-cancer-summit-advancements-in-sclc-presentation-april-29-2023

05/18/2023

Modern problems require modern solutions. Henlius is leading the pack with our innovative treatment of both extensive-stage and limited-stage small cell lung cancer using with chemotherapy.

Learn more: https://www.smallcelllungcancertrial.com/

05/16/2023

Smoking to***co can elevate your risk of developing small cell lung cancer, even after quitting. At Henlius, we have seen great success treating SCLC in both Europe and Asia using

Apply to one of our clinical trials in the US to see if Serplulimab can help you treat your limited-stage or extensive-stage small cell lung cancer.

Learn more: https://www.smallcelllungcancertrial.com/find-a-clinical-trial

04/27/2023

Dr. Nitika Sharma, medical oncologist and hematologist at Cancer Treatment Centers of America Atlanta, thinks comprehensive frontline treatments -- using chemotherapy alongside targeted therapy and immunotherapy agents like Serplulimab -- have the potential to vastly improve outcomes for small cell lung cancer patients, similar to the success doctors have seen treating the non–small cell lung cancer population.

Read more in her recent interview with Targeted Oncology: https://www.targetedonc.com/view/room-to-grow-in-the-small-cell-lung-cancer-treatment-landscape

04/25/2023

Medical researchers say new AI tool Sybil "accurately predicted lung cancer within a year 86% to 94% of the time" in a recent study published in the Journal of Clinical Oncology.

Read More: https://www.webmd.com/lung-cancer/news/20230412/ai-tool-can-detect-early-signs-of-lung-cancer-researchers-say

04/13/2023

Our trial for Limited-Stage Small Cell Lung Care patients compares the effectiveness of a new investigational drug, Serplulimab, when it’s combined with chemotherapy and radiation therapy to the current standard of care, which is just chemotherapy and radiation.

Find out if you qualify for the trial: https://www.smallcelllungcancertrial.com/limited-stage

Address

430 N. McCarthy Boulevard
Milpitas, CA

Website

https://www.smallcelllungcancertrial.com/

Alerts

Be the first to know and let us send you an email when Hengenix, A Henlius Company posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hengenix, A Henlius Company: